In order to strengthen their position as market-leaders in bioanalytical support for drug development studies, Unilabs and Biomonitor announced today the cooperation on measuring anti-drug antibodies (ADA) to biologicals.

Unilabs and Biomonitor will jointly promote immunogenicity testing to the drug development industries. This comprehensive service includes antibody screening, confirmatory assays and cell based neutralising assays.

Yvonne Lech, Managing Director of Unilabs Denmark, stated: “Together Unilabs and Biomonitor will become a major force in CRO support for the development of biologicals providing high quality services to the pharmaceutical and biotechnology industries. Unilabs’ vast experience in bioanalysis and Biomonitor’s experience in developing specialised cell based assays will enable us to offer customers complete support for regulatory compliant development of new biopharmaceuticals and biosimilars”.

Unilabs Drug Development Services are delivered from GLP-certified laboratories in York and Copenhagen and were established with the aim of bringing a fresh approach to contract bioanalytical research offering unsurpassed quality and delivery with scientific excellence.

Biomonitor supports pharma/biotech companies with PK and PD and has many years of experience in developing highly specialized cell-based assays, some of which are currently being used to monitor patients suffering from multiple sclerosis, rheumatoid arthritis and Crohn’s disease.

Arsalan Kharazmi, CEO of Biomonitor, says, “Cooperating with Unilabs on measuring neutralizing antibodies has the exciting benefit of allowing for the provision of complete bioanalytical services for pre-clinical as well as clinical phases of biopharmaceutical and biosimilar drug development.”

For more information please visit www.unilabs.com and www.biomonitor.dk
OR please contact:
Yvonne Lech, Managing Director Unilabs a.s.
Telephone: +45 23 44 12 84; email: yvonne.lech@unilabs.com

Arsalan Kharazmi, CEO Biomonitor A/S
Telephone: +45 39 17 97 97; email: ak@biomon.dk